此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Retrospective Study of the Safety and Efficacy of Patients With RVO in Subjects Who Completed Parent Study CLS1003-201

2019年12月19日 更新者:Clearside Biomedical, Inc.

Retrospective Study of the Safety and Efficacy of Suprachoroidal CLS-TA in Combination With Intravitreal Aflibercept for the Treatment of Macular Edema Associated With RVO in Subjects Who Completed Parent Study CLS1003-201

The purpose of this non interventional retrospective study is to continue to collect data from patients following their completion of Protocol CLS 1003-201: "Safety and Efficacy of Suprachoroidal CLS-TA with Intravitreal Aflibercept in Subjects with Macular Edema Following Retinal Vein Occlusion" (ie, the parent study).

研究概览

地位

完全的

详细说明

This is a non-interventional, retrospective study of up to 6 months for subjects that completed the parent study CLS1003-201. This study is designed to collect data from patients following their parent study exit visit, through either the time of the next treatment for RVO or at least 6 months following the parent study exit visit, whichever occurs first.

During this non-interventional retrospective study, the following data will be collected in an online questionnaire (or where required, on paper) provided by Clearside:

  • Next RVO therapy administered (if applicable), including reason for treatment
  • Continued documentation of current or changes in medical or ocular conditions following parent study
  • Concomitant drug or therapy changes
  • Visual acuity, including details on the method used in the assessment
  • Central retinal thickness, including details on the equipment used in its determination
  • Intraocular pressure, including details on the equipment used in its determination

Subjects will be selected based on parent study primary investigator's access to their medical records access, following exit from CLS1003-201. Data will also be collected on the total number of patients included in this non interventional study as well as reasons patients were excluded. Data will be summarized from the randomization treatment assignment in the parent study.

研究类型

观察性的

注册 (实际的)

20

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • Texas
      • San Antonio、Texas、美国

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

有资格学习的性别

全部

取样方法

非概率样本

研究人群

The study population will include approximately 30 adult subjects whose parent study primary investigator has access to their medical records, following exit from CLS1003-201.

描述

Inclusion Criteria:

  • Completed enrollment and did not receive additional aflibercept therapy in the Parent study, CLS1003-201

Exclusion Criteria:

  • N/A

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

队列和干预

团体/队列
CLS1003-201
Those subjects whose parent study primary investigator has access to their medical records, following exit from CLS1003-201.

研究衡量的是什么?

主要结果指标

结果测量
大体时间
Time to additional therapy for RVO
大体时间:6 months following exit from Parent study
6 months following exit from Parent study

次要结果测量

结果测量
措施说明
大体时间
Mean change from baseline for intraocular pressure
大体时间:6 months following exit from Parent study
Measured by applanation tonometry
6 months following exit from Parent study
Mean change from baseline in central subfield thickness
大体时间:6 months following exit from Parent study
Based on spectral domain optical coherence tomography
6 months following exit from Parent study
Mean change from baseline in best corrected visual acuity
大体时间:6 months following exit from Parent study
Based on ETDRS
6 months following exit from Parent study

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 研究主任:Thomas Ciulla, MD、Clearside Biomedical, Inc.

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始

2016年11月1日

初级完成 (实际的)

2017年4月12日

研究完成 (实际的)

2017年4月12日

研究注册日期

首次提交

2016年11月3日

首先提交符合 QC 标准的

2016年11月3日

首次发布 (估计)

2016年11月6日

研究记录更新

最后更新发布 (实际的)

2019年12月20日

上次提交的符合 QC 标准的更新

2019年12月19日

最后验证

2019年12月1日

更多信息

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

3
订阅